Core Insights - The stock price of Tailin Biological closed at 27.2 yuan on November 27, with a 4.90% increase, resulting in a rolling PE ratio of 200.29 times and a total market capitalization of 3.297 billion yuan [1] - The average PE ratio in the medical device industry is 51.68 times, with a median of 40.10 times, placing Tailin Biological at the 114th position in the industry ranking [1] - As of September 30, 2025, the number of shareholders for Tailin Biological decreased by 1,487 to 9,437, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, process analysis, and protective measures, providing high-quality products and solutions for various industries including biomedicine, healthcare, food and beverage, and environmental protection [2] - The company has a portfolio of 419 technology patents, including 55 invention patents, and has participated in the formulation of 35 national and industry standards, with 17 of those as the first author [2] - Tailin Biological has undertaken three key projects under the "13th Five-Year National Science and Technology Innovation Plan" and received an award for technological innovation from the China Pharmaceutical Equipment Industry Association [2] Financial Performance - In the latest quarterly report for Q3 2025, Tailin Biological reported revenue of 213 million yuan, a year-on-year decrease of 12.08%, while net profit increased by 30.13% to 14.7233 million yuan, with a gross profit margin of 52.59% [2]